Singapore Non Invasive Prenatal Testing Market Size & Outlook
Related Markets
Singapore non invasive prenatal testing market highlights
- The Singapore non invasive prenatal testing market generated a revenue of USD 15.2 million in 2023 and is expected to reach USD 29.4 million by 2030.
- The Singapore market is expected to grow at a CAGR of 10% from 2024 to 2030.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2023.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
Non invasive prenatal testing market data book summary
| Market revenue in 2023 | USD 15.2 million |
| Market revenue in 2030 | USD 29.4 million |
| Growth rate | 10% (CAGR from 2024 to 2030) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
Other key industry trends
- In terms of revenue, Singapore accounted for 0.4% of the global non invasive prenatal testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China non invasive prenatal testing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 247.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non Invasive Prenatal Testing Market Scope
Non Invasive Prenatal Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| MedGenome | View profile | 501-1000 | Bangalore, Karnataka, India, Asia | https://diagnostics.medgenome.com |
| CooperSurgical | View profile | 501-1000 | Trumbull, Connecticut, United States, North America | http://www.coopersurgical.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | https://www.bioratherapeutics.com/ |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | https://www.centogene.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Natera Inc | View profile | 3293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | https://www.natera.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
Singapore non invasive prenatal testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 57.24% in 2023. Horizon Databook has segmented the Singapore non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
The penetration of NIPT is high in the country. Developed healthcare infrastructure, high adoption of NIPT among high-risk women, high disposable income, and presence of global players in the country are some of the key factors boosting the adoption of NIPT in the country.
In Singapore, NIPT services were introduced in 2013 and are now more broadly utilized, although it is currently available only in private facilities. Down syndrome screening is routinely provided to all pregnant women regardless of age. Harmony Test, Panorama Test, and iGene NIPT are the most common tests offered in the country.
NIPT via the analysis of cell-free fetal DNA from the mother's plasma has recently become commercially available in the country. Strategic initiatives by local market players such as new product launches are expected to further boost the market.
Reasons to subscribe to Singapore non invasive prenatal testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Singapore non invasive prenatal testing market databook
-
Our clientele includes a mix of non invasive prenatal testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Singapore non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Singapore non invasive prenatal testing market size, by gestation period, 2018-2030 (US$M)
Singapore Non Invasive Prenatal Testing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
